KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Thermo Fisher Scientific (TMO) Accounts Payables (2016 - 2025)

Thermo Fisher Scientific (TMO) has disclosed Accounts Payables for 16 consecutive years, with $2.6 billion as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Accounts Payables rose 3.91% year-over-year to $2.6 billion, compared with a TTM value of $2.6 billion through Sep 2024, up 3.91%, and an annual FY2023 reading of $2.9 billion, down 15.05% over the prior year.
  • Accounts Payables was $2.6 billion for Q3 2024 at Thermo Fisher Scientific, up from $2.5 billion in the prior quarter.
  • Across five years, Accounts Payables topped out at $3.4 billion in Q4 2022 and bottomed at $1.4 billion in Q2 2020.
  • Average Accounts Payables over 5 years is $2.4 billion, with a median of $2.5 billion recorded in 2023.
  • The sharpest move saw Accounts Payables soared 51.48% in 2021, then dropped 15.05% in 2023.
  • Year by year, Accounts Payables stood at $2.2 billion in 2020, then soared by 31.82% to $2.9 billion in 2021, then rose by 17.93% to $3.4 billion in 2022, then decreased by 15.05% to $2.9 billion in 2023, then decreased by 9.26% to $2.6 billion in 2024.
  • Business Quant data shows Accounts Payables for TMO at $2.6 billion in Q3 2024, $2.5 billion in Q2 2024, and $2.6 billion in Q1 2024.